Unimolecular and bimolecular binding system for the prediction of CYP2D6-mediated metabolism

Drug Metabolism and Disposition

Volumn 40, Issue 3, 2012, Pages 486-496

  Sato, Kimihiko ^a,b   Yamazoe, Yasushi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DULOXETINE; MEQUITAZINE; METOPROLOL; MEXILETINE; MIANSERIN; NAPHTHALENE; PARACETAMOL; PERHEXILINE; PHENYTOIN; QUINOLINE; TERFENADINE; TROPISETRON;

ANALYTIC METHOD; ARTICLE; BIMOLECULAR BINDING SYSTEM; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME SPECIFICITY; ENZYME SUBSTRATE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UNIMOLECULAR BINDING SYSTEM; VALIDATION STUDY;

BINDING SITES; CYTOCHROME P-450 CYP2D6; HUMANS; MODELS, MOLECULAR; SUBSTRATE SPECIFICITY;

EID: 84863162356     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.043125     Document Type: Article

References (27)

1. Arlt VM, Hewer A, Sorg BL, Schmeiser HH, Phillips DH, and Stiborova M (2004) 3-Aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone, forms DNA adducts after metabolic activation by human and rat liver microsomes: evidence for activation by cytochrome P450 1A1 and P450 1A2. Chem Res Toxicol 17:1092-1101. (Pubitemid 39108677)
2. Arlt VM, Stiborova M, Hewer A, Schmeiser HH, and Phillips DH (2003) Human enzymes involved in the metabolic activation of the environmental contaminant 3-nitrobenzanthrone: evidence for reductive activation by human NADPH:cytochrome P450 reductase. Cancer Res 63:2752-2761. (Pubitemid 36667145)
3. Barclay ML, Sawyers SM, Begg EJ, Zhang M, Roberts RL, Kennedy MA, and Elliott JM (2003) Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics 13:627-632. (Pubitemid 37311149)
4. Dalén P, Frengell C, Dahl ML, and Sjöqvist F (1997) Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit 19:543-544.
5. de Groot MJ, Ackland MJ, Horne VA, Alex AA, and Jones BC (1999) Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. J Med Chem 42:1515-1524. (Pubitemid 29226723)
6. de Groot MJ, Vermeulen NP, Kramer JD, van Acker FA, and Donné-Op den Kelder GM (1996) A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108. Chem Res Toxicol 9:1079-1091. (Pubitemid 26347960)
7. De Rienzo F, Fanelli F, Menziani MC, and De Benedetti PG (2000) Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4. J Comput Aided Mol Des 14:93-116. (Pubitemid 30103825)
8. Granfors MT, Backman JT, Laitila J, and Neuvonen PJ (2004) Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro. Br J Clin Pharmacol 57:349-353. (Pubitemid 38296999)
9. Härtter S, Dingemanse J, Baier D, Ziegler G, and Hiemke C (1996) The role of cytochrome P450 2D6 in the metabolism of moclobemide. Eur Neuropsychopharmacol 6:225-230. (Pubitemid 26281561)
10. Islam SA, Wolf CR, Lennard MS, and Sternberg MJ (1991) A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis 12:2211-2219.
11. Koehl W, Amin S, Staretz ME, Ueng YF, Yamazaki H, Tateishi T, Guengerich FP, and Hecht SS (1996) Metabolism of 5-methylchrysene and 6-methylchrysene by human hepatic and pulmonary cytochrome P450 enzymes. Cancer Res 56:316-324. (Pubitemid 26026360)
12. Koyama N and Yamazoe Y (2011) Development of two-dimensional template system for the prediction of CYP2B6-mediated reaction sites. Drug Metab Pharmacokinet 26:309-330.
13. Koymans L, Vermeulen NP, van Acker SA, te Koppele JM, Heykants JJ, Lavrijsen K, Meuldermans W, and Donné-Op den Kelder GM (1992) A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 5:211-219.
14. Mancy A, Antignac M, Minoletti C, Dijols S, Mouries V, Duong NT, Battioni P, Dansette PM, and Mansuy D (1999) Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry 38: 14264-14270.
15. Matsumoto K, Nemoto E, Hasegawa T, Akimoto M, and Sugibayashi K (2011) In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone. Biol Pharm Bull 34:734-739.
16. Meyer UA, Gut J, Kronbach T, Skoda C, Meier UT, Catin T, and Dayer P (1986) The molecular mechanisms of two common polymorphisms of drug oxidation: evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 16:449-464. (Pubitemid 16076723)
17. Moors SL, Vos AM, Cummings MD, Van Vlijmen H, and Ceulemans A (2011) Structure-based site of metabolism prediction for cytochrome P450 2D6. J Med Chem 54:6098-6105.
18. Nakajima M, Itoh M, Sakai H, Fukami T, Katoh M, Yamazaki H, Kadlubar FF, Imaoka S, Funae Y, and Yokoi T (2006) CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. Int J Cancer 119:2520-2526. (Pubitemid 44691304)
19. Nakajima T, Wang RS, Elovaara E, Gonzalez FJ, Gelboin HV, Raunio H, Pelkonen O, Vainio H, and Aoyama T (1997) Toluene metabolism by cDNA-expressed human hepatic cytochrome P450. Biochem Pharmacol 53:271-277. (Pubitemid 27112943)
20. Sai Y, Yang TJ, Krausz KW, Gonzalez FJ, and Gelboin HV (1999) An inhibitory monoclonal antibody to human cytochrome P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver. Pharmacogenetics 9:229-237. (Pubitemid 29359005)
21. Salsali M, Holt A, and Baker GB (2004) Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol 24:63-76. (Pubitemid 38233730)
22. Vickers AE, Sinclair JR, Zollinger M, Heitz F, Glänzel U, Johanson L, and Fischer V (1999) Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos 27:1029-1038. (Pubitemid 29409639)
23. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208. (Pubitemid 39410902)
24. Wolff T, Distlerath LM, Worthington MT, Groopman JD, Hammons GJ, Kadlubar FF, Prough RA, Martin MV, and Guengerich FP (1985) Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res 45:2116-2122. (Pubitemid 15024394)
25. Yamaura Y, Yoshinari K, and Yamazoe Y (2011) Predicting oxidation sites with order of occurrence among multiple sites for CYP4A-mediated reactions. Drug Metab Pharmacokinet 26:351-363.
26. Yamazaki H, Inoue K, Mimura M, Oda Y, Guengerich FP, and Shimada T (1996) 7-Ethoxy-coumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. Biochem Pharmacol 51:313-319. (Pubitemid 26054438)
27. Yamazoe Y, Ito K, and Yoshinari K (2011) Construction of a CYP2E1-template system for prediction of the metabolism on both site and preference order. Drug Metab Rev 43:409-439.